ArticleEsophagus : official journal of the Japan Esophageal Society2026
Radial incision and balloon dilation for benign esophageal stenosis: initial clinical experience with exploratory historical comparison.
Article in Esophagus : official journal of the Japan Esophageal Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndoscopic balloon dilation (EBD) is the standard treatment for benign esophageal stenosis (BES), but restenosis is common. Although EBD with triamcinolone acetonide injection (EBD-TA) reduces restenosis, dense fibrotic stenoses often show limited distensibility. We introduced a modified endoscopic dilation technique, radial incision and balloon dilation (RIBD), which integrates longitudinal incisions with balloon dilation and adjunctive TA injection, and evaluated its initial clinical outcomes in patients with BES.
methodsThis retrospective single-center study included 66 patients who underwent endoscopic treatment for BES. RIBD was introduced in 2022, and its initial clinical outcomes were assessed with historical comparison with EBD and EBD-TA. The primary outcome was restenosis. Secondary outcomes were the number of dilation sessions, refractory stenosis, and adverse events.
resultsRIBD was used as the sole treatment in 15 patients and as secondary treatment in 12. Restenosis after RIBD occurred in 1/15 patients (6.7%) in the single-method group and 2/12 (16.7%) in the multiple-methods group. The median number of dilation sessions was 1 (IQR, 1-1) in both groups. No refractory stenosis or adverse events were observed after RIBD. In exploratory historical comparisons, RIBD was associated with lower restenosis rates and fewer dilation sessions than both EBD and EBD-TA.
conclusionRIBD is a modified endoscopic dilation technique that improves the extensibility of fibrotic esophageal stenoses while minimizing deep mucosal injury, and may represent a useful treatment option in selected patients with BES. KEY WORDS: esophageal stenosis; balloon dilation; restenosis; triamcinolone acetonide; radial incision.
Indexed as
Identifiers
42474876What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.